
Opinion|Videos|January 31, 2025
Latest Trends and Innovations in CLL and MCL Treatment
Advertisement
Episodes in this series

Advertisement
Related to this article

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

During OncoVenture, Careology leaders described how their platform supports patients receiving CAR T-cell therapy at home in Ohio, extends Mayo Clinic’s reach in rural Florida, and powers payer care navigation.

John Elliott, of Reimagine Care, outlined a model that pairs AI-supported triage with oncology-trained nurses, and the CEO of a large Texas practice described how the partnership has grown to include patients receiving CAR T-cell therapy.

Anemia and iron deficiency are linked to higher odds of acute heart failure during pregnancy and after childbirth, according to a study.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic
3
Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say
4
Low CRC Incidence Found After Endoscopic Mucosal Resection
5




